Purpose Several observational studies suggest that metformin reduces incidence cancer risk; however, many of these studies suffer from time-related biases and several cancer outcomes have not been investigated due to small sample sizes. Methods We constructed a propensity score-matched retrospective cohort of 84,434 veterans newly prescribed metformin or a sulfonylurea as monotherapy. We used Cox proportional hazard regression to assess the association between metformin use compared to sulfonylurea use and incidence cancer risk for 10 solid tumors. We adjusted for clinical covariates including hemoglobin A1C, antihypertensive and lipid-lowering medications, and body mass index. Incidence cancers were defined by ICD-9-CM codes. Results Among 42,217 new metformin users and 42,217 matched-new sulfonylurea users, we identified 2,575 incidence cancers. Metformin was inversely associated with liver cancer (adjusted hazard ratio [aHR] = 0.44, 95% CI 0.31, 0.64) compared to sulfonylurea. We found no association between metformin use and risk of incidence bladder, breast, colorectal, esophageal, gastric, lung, pancreatic, prostate, or renal cancer when compared to sulfonylurea use. Conclusions In this large cohort study that accounted for time-related biases, we observed no association between the use of metformin and most cancers; however, we found a strong inverse association between metformin and liver cancer. Randomized trials of metformin for prevention of liver cancer would be useful to verify these observations.
Introduction
Metformin-a biguanide, the glycemic lowering effects of which are not entirely understood-is indicated for the treatment and prevention of type 2 diabetes. The primary known effect of metformin is to decrease hepatic glucose output and increase glucose utilization in muscle [1] . Metformin also decreases circulating free fatty acids [2] , activates AMP-activated protein kinase [3] , and inhibits the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (mTOR) signaling pathway which reduces cell proliferation and promotes apoptosis [4] . Additionally, metformin reduces the mitochondrial production of adenosine triphosphate through binding to complex I of the electron transport chain in hepatocytes [5] . These direct cellular effects, coupled with the known ability of metformin to reduce circulating insulin levels, support a plausible mechanism for metformin's cancer inhibitory actions.
Several observational studies have investigated the impact of metformin use on cancer incidence. Meta-analyses of observational studies have been conducted for colorectal [6, 7] , hepatocellular [7] [8] [9] [10] , breast [11] , lung [7, 12, 13] , pancreatic [14, 15] , prostate [16] , and all cancer events combined [7, [17] [18] [19] [20] . In many of these studies, metformin use was associated with cancer risk reductions, sometimes as high as 94%. Nevertheless, several of these previous studies have serious methodological flaws resulting from timerelated biases [21] . A recent meta-analysis which included the eight published studies that were free of time-related biases reported a summary risk estimate of 0.90 (95% CI 0.89, 0.91) for the association between metformin and any cancer incidence [19] . For individual cancers, the number of studies that accounted for time-related biases was smaller ranging from only three studies of lung cancer to six for breast and prostate cancer.
Given the uncertainty regarding the impact of metformin use on cancer incidence rates and the paucity of studies that have not incurred time-related biases and accounted for important confounders such as body mass index and glycemic control, we used a large retrospective cohort of patients with diabetes cared for within the Veterans Health Administration who initiated treatment with metformin or a sulfonylurea to determine the association between metformin and the incidence of 10 solid tumors.
Materials and methods

Study design and data sources
We constructed a retrospective cohort of veterans initiating an oral antidiabetes drug between October 1, 2001 and September 30, 2008 using national Veterans Health Administration (VHA) databases. Details on this cohort have been published previously [22] [23] [24] . Briefly, these data included outpatient and inpatient healthcare encounters (coded using 
Study population
The study population included veterans who were aged 18 years or older, active users of the VHA health system (defined as at least two clinical encounters or prescription fill occurring over the past 730 days), and had a new prescription dispensed for either metformin or a sulfonylurea (glyburide, glipizide, glimepiride). This new prescription was the first prescription dispensed after 180 days without prescriptions filled for any hypoglycemic medication. The date of the new prescription represents the cohort entry date.
For this study, we excluded individuals who were not prescribed either metformin or sulfonylurea monotherapies, had a baseline cancer diagnosis, or had a creatinine level greater than or equal to 132.6 µmol/L (1.5 mg/dL) ( Fig. 1) . During the study period, metformin was not recommended for patients with a creatinine exceeding this threshold. To ensure that we were correctly classifying exposure time, we excluded patients who were not persistent with their initial monotherapy regimen within the first 12 months of observation.
Exposures
The primary exposure was persistent use of metformin or sulfonylureas (glyburide, glipizide, glimepiride). We used pharmacy information of pills dispensed and prescribed days' supply to determine individual patients' drug exposure. Persistent use of a medication was defined as continuous use with no gaps in medication use greater than 90 days.
To address potential latency bias, we included a 12-month lag period to remove patients who developed cancer (see below) or died within the first year after initiating metformin or a sulfonylurea. Thus, follow-up began 12 months after the initial antidiabetic prescription date and continued through the 181st day of no medical contact (inpatient, outpatient, or pharmacy use); non-persistence on the original monotherapy (addition of another antidiabetic medication or the 91st day without drug available); a study outcome; and reaching a serum creatinine level of 132.6 µmol/L (1.5 mg/dL), death, or end of study.
Cancer outcomes
The primary outcome was a new diagnosis of a study cancer. Cancer diagnosis outcomes were defined by ICD-9-CM codes. Definitions included the following: bladder (ICD-9-CM codes 188.x); breast (ICD-9-CM codes 174x, 175.x); colorectal (ICD-9-CM codes 153.x, 154.x); esophageal (ICD-9-CM codes 150.x); gastric (ICD-9-CM codes 151.x); liver (ICD-9-CM codes 155.x); lung (ICD-9-CM codes 162.x); pancreas (ICD-9-CM codes 157.x); prostate (ICD-9-CM codes 185.x); and renal (ICD-9-CM codes 189.x) [25] .
Covariates
Study covariates were collected at 730 days prior to medication initiation. Covariates included but were not limited to age, sex, race (white, black, other), date of cohort entry, body mass index, blood pressure, glomerular filtration rate, hemoglobin A1c (HbA1c), low-density lipoprotein levels, smoking status, select medications (statins, aspirin, antihypertensives, anticoagulants, antiarrhythmic, diuretics, antipsychotics, glucocorticoids), comorbid illnesses (cardiovascular disease, severe mental illness, cardiac valvular disease, arrhythmias, Parkinson's disease, chronic obstructive pulmonary disease, liver disease), number of medications, and number of outpatient visits. Liver diseases were further characterized by individual conditions including acute/ subacute necrosis of the liver, chronic liver disease/cirrhosis, liver abscess and sequelae, and other liver diseases. Covariate definitions are presented in Online Resource Table 1 .
Statistical Analysis
The primary analysis was the time to each individual cancer diagnosis in a propensity score-matched cohort. We constructed separate Cox proportional hazard regression models to estimate the adjusted hazard ratios and 95% twosided confidence intervals for the association of metformin compared to sulfonylureas and specific incidence cancers. The Cox proportional hazard regression models were estimated using the cph fitting function in the rms [26] package in R (available at: http://www.r-proje ct.org). For each model, the outcome was a specific incidence cancer, and the occurrence of other cancers did not end followup. The covariates used in the regression are described in Online Resource Table 1 and Online Resource Table 2 . They were selected based on prior knowledge and previous studies exploring the use of metformin and sulfonylureas in a cohort of U.S. Veterans [22] [23] [24] . Continuous covariates were modeled using restricted cubic splines (rcs) with three knots to account for non-linearity. Missing covariates were handled with multiple imputations using predictive mean matching with bootstrapping [27] . All covariates from the adjusted analysis as well as an indicator for each Veterans Integrated Service Networks were included in twenty imputation models to compute final estimates. The hazard function for the Cox proportional hazards regression model is given in Online Resource Fig. 5 . The propensity score modeled the probability of metformin use given baseline study covariates. Visual inspection of the propensity score distributions between metformin and sulfonylurea users showed good overlap. Propensity score distributions are presented in Online Resource Fig. 1 . Metformin and sulfonylurea observations were matched using an 8-to-1 digit matching algorithm, yielding 84,434 propensity score-matched observations (42,217 in each exposure group). Odds ratios for being prescribed metformin are presented in Online Resource Table 2 .
Sensitivity and subgroup analysis
In an approach similar to the intention-to-treat analysis used in clinical trials, we conducted a sensitivity analysis ignoring subsequent changes to the medication regimen (persistent exposure not required [PENR] ). To evaluate the dose effects, we determined the daily dose amount of metformin users in our cohort and the beginning of the follow-up and divided this by the defined daily dose (DDD) of metformin (2 g/day) [28] . The DDD factors were separated based on the cohort distribution and categorized as less than 0.5 of the DDD (32.1%, n = 9,943), equal to 0.5 of the DDD (48.4%, n = 20,424) and greater than 0.5 of the DDD (28%, n = 11,850). We conducted additional adjusted analyses comparing the metformin DDD level to sulfonylurea users. Furthermore, given that prior studies have suggested that statin use could impact the risk of cancer [29, 30] , we conducted additional stratified analyses by statin use at baseline (yes or no), and baseline cirrhosis as defined by ICD-9-CM codes (Online Resource Table 1 ) (yes or no). We formally tested for an interaction between statin medication use and cirrhosis, and metformin use by including cross-product terms in our regression models.
In addition, we conducted a sensitivity to unmeasured confounding analysis, quantifying the required prevalence difference between exposures that a hypothetical unmeasured binary confounder would need to tip statistically significant results into non-significant results [31] . In all models, sulfonylurea users were the reference group. Statistical analyses were conducted using R (available at: http://www.rproje ct.org) and SAS for Windows 9.2 (SAS Institute, Cary, NC).
Results
In the full, unmatched cohort, we identified 257,563 incidence prescriptions for metformin or a sulfonylurea monotherapy. During the 12-month lag period, we excluded 6,810 (2.6%) patients due to death, 4,164 (1.6%) with a new cancer diagnosis, 9,844 (3.8%) lost to follow-up, 82,904 (32.2%) who were non-persistent on the initial regimen or who added a new medication, and 15,978 (6.2%) who developed a creatinine level greater than 132.6 µmol/L (1.5 mg/dL) (Fig. 1) .
Patient characteristics
Demographic characteristics of the full and propensitymatched cohort are presented in Table 1 . After propensity score matching, metformin and sulfonylurea baseline characteristics were similar (Table 1 ) and standardized differences in the proportion with these characteristics were negligible (Online Resource Fig. 2 ).
Primary outcome: individual cancer outcomes
Event counts, person-years, event rates, and unadjusted and adjusted hazard ratios for each cancer outcome are presented in Table 2 and Fig. 2 . In the primary analysis, requiring persistent medication exposure, we identified 43 incidence liver cancers during 83,290 person-years of follow-up among metformin users and 83 during 69,319 person-years of follow-up among sulfonylurea users for an event rate of 0.5 (95% CI 0.4, 0.7) and 1.2 (95% CI 1.0, 1.5) per 1,000 person-years, respectively. 75% (94) were hepatocellular carcinomas, 10% (12) were cholangiocarcinoma, and 16% (20) were primary liver cancers NOS. The adjusted hazard ratio for the association with liver cancer in metformin users compared to sulfonylureas users was 0.44 (95% CI 0.31, 0.65). We found no evidence of an association between metformin use and bladder, breast, colorectal, esophageal, gastric, lung, pancreatic, prostate, or renal cancers when compared to sulfonylurea users (Fig. 2) .
Sensitivity analyses
We conducted a sensitivity analysis removing the requirement for patients to be adherent to their initially prescribed medication (i.e., persistent exposure not required). This resulted in an additional 4,548 cancer outcomes, including 269 liver cancers. In this analysis, the association remained When the propensity score-matched cohort was stratified by statin use at baseline, the unadjusted hazard ratio of metformin with liver cancer risk was 0.61 (95% 0.31, 1.19) among patients with statin use at baseline versus 0.38 (95% CI 0.24, 0.59) in individuals without statin prescriptions at baseline (Online Resource Fig. 4) . We found no evidence of an interaction between baseline statin use and metformin on any cancer outcomes when persistence with treatment was required (Online Resource Table 3 ). In subgroup analysis stratified by cirrhosis at baseline, metformin compared to sulfonylurea was associated with liver cancer in both patients with (HR 0.32, 95% CI 0.12, 0.89) and without (HR 0.46, 95% CI 0.31, 0.68) baseline cirrhosis (Online Resource  Table 4 ).
We estimated the distribution of a hypothetical unmeasured confounder that could explain the statistically significant association observed between metformin and liver cancer. We found that an unmeasured binary confounder that increased one's risk of cancer with a hazard ratio of 2 would need a 54% prevalence difference, e.g., it occurs in 54% of the sulfonylurea users and none of the metformin users, to render our main findings statistically non-significant. In the persistent exposure that did not require analysis, the prevalence difference would need to be 75%.
Discussion
We found a strong inverse association between metformin use compared to sulfonylurea use and incidence liver cancer. In contrast, metformin compared to sulfonylurea use was not associated with incidence bladder, breast, colorectal, esophageal, gastric, lung, pancreas, prostate, or renal cancer in the primary analysis. The protective association observed with liver cancer was consistently observed in patients with and without baseline liver diseases and in patients with and without baseline use of statin medications. a Full cohort descriptive information is presented for comparison purposes and the propensity-matched cohort was used for all analyses Our findings are important as only a limited number of pharmacoepidemiological studies have been conducted that are both free of time-related biases and able to adjust for important confounders such as BMI and glycemic control [21, 32] . Gandini et al. conducted a meta-analysis including a sub-analysis restricted to the eight studies they considered to be free of time-related biases [19] . Three of those studies included risk ratios for hepatocellular cancer. In the analyses that used sulfonylurea medications as the comparator group, the summary risk ratio (SRR) for hepatocellular cancer was 0.65 (95% CI 0.39, 1.08). These studies did not account for body mass index, glycemic control, or statin use. Similar to our study, no association was found between metformin use and prostate or pancreatic cancer. Gandini et al. also found significant associations between metformin and colorectal cancer (SRR = 0.92, 95% CI 0.85, 0.98) and lung cancer (SRR = 0.88, 95% CI 0.81, 0.95), similar to our findings in the secondary analyses that did not require persistent exposure.
Tsilidis et al. recently published a study including 95,820 participants in the Clinical Practice Research Datalink that examined the association of metformin use compared to sulfonylurea use and cancer risk [33] . They included a similar lag period and employed a new-user design to avoid time-related biases and did not require persistent exposure to the original regimen, similar to our secondary analysis which did not require persistent exposure. However, they attempted to account for variable adherence to the original study regimens during the follow-up period. In that study, no significant association with metformin and any cancer evaluated was found. Similar, albeit non-statistically significant HR was found with lung cancer (HR = 0.85; 95% CI 0.68, 1.07; total cases = 468) and colorectal cancer (HR = 0.92; 95% 0.76, 1.13; total cases = 599). There was a weak non-statistically significant association with liver cancer (HR = 0.85; 95% CI 0.49, 1.48) based on only 74 liver cancer cases, compared to 395 cases in our similar analysis. This cohort had a much higher percentage of women than our study which could contribute to the differences in study results.
We found a very strong inverse association between metformin use and liver cancer. Although our findings might be explained by residual confounding, we made extensive efforts to minimize this concern. Prescribers may avoid metformin in persons with liver disease, which may in turn increase the risk of liver cancer. Indeed, in the unmatched cohort, liver disease was more common in sulfonylurea users than metformin users. Our propensity score matching strategy included a comprehensive list of relevant covariates, and specifically assured that the observed liver disease was similar in both exposure groups. Analyses stratified by baseline liver disease yielded consistent inverse associations in both strata. Furthermore, in our analysis that evaluated the sensitivity of our findings to a potential unmeasured confounder, we estimated that the observed effect size could only be explained by an unmeasured confounder moderately associated with the outcome, but with a very different prevalence in the two comparison groups.
The precise explanation for the observed selective inverse association between metformin use and incidence liver cancer is unclear [34] . However, the major target of metformin is the liver, with liver tissue being one of the few sites that express OCT1, the major transporter associated with metformin uptake [35] . In addition, the current clinically used dosages of metformin are expected to yield higher drug concentrations in the portal circulation compared to the systemic circulation. The increased uptake and portal circulation exposure might allow the liver to achieve higher drug concentrations than other tissues. Nevertheless, indirect cancer-inhibitory effects of metformin, such as reducing insulin sensitivity or weight reduction, could also be beneficial for tumor prevention. Our study has several strengths. Our new-user design allowed us to minimize time-related biases and is more similar to a clinical trial where drug exposure starts at study entry [21, 36] . We applied a number of steps to minimize exposure misclassification in our primary analyses and focused on identifying incidence cancers during follow-up by considering a lag period to support the plausibility of the observed associations. Finally, we were able to adjust for important covariates that few prior studies have been able to account for such as body mass index, glycemic control, and use of statin medications. There are several limitations as well. First, our use of administrative codes could have resulted in misclassification of some cancer outcomes as well as some important covariates. We have conducted a validation study of NSAID and tobacco use and found these codes to be quite accurate [37] . An important limitation is that we were unable to adjust for alcohol use. If alcohol consumption influences whether an individual was initiated on metformin or a sulfonylurea, this could have introduced confounding into our analysis. We were also unable to account for the overall duration of diabetes in the cohort. We utilized a new-user design which should result in individuals with similar disease duration being entered into the cohort; however, residual confounding by this variable could still persist. In addition, we were unable to investigate the impact of insulin and cancer risk which has been previously associated with cancer risk; however, the associations have been limited by methodological concerns of the study design [38, 39] . Another limitation is that the association with metformin use might represent a result of a protective effect of metformin versus a harmful effect of sulfonylureas. Our overall event rates for all cancers were higher than SEER estimates in men over the age of 50 years which is likely related to the increased prevalence of risk factors in our VHA population (diabetes, obesity, alcohol and tobacco current and former use). Nevertheless, the liver cancer event rate in sulfonylurea users was quite high. Our study is unable to determine the exact contribution toward liver cancer risk made by metformin or sulfonylureas but suggests a relative benefit with metformin compared to sulfonylureas.
In conclusion, in a large, nationwide cohort of diabetic patients newly initiated on an oral antidiabetic agent, we found that metformin use was associated with a 56% reduction in liver cancer risk. We did not demonstrate risk reductions for bladder, breast, esophageal, gastric, pancreatic, prostate, or renal cancer. Our study design avoided timerelated biases. Our findings were consistent across multiple sensitivity analyses, and our analyses suggest that only a very prevalent and strong unmeasured confounder could explain our effect sizes. Given the strong observed association with liver cancer with no similar finding in the other nine solid tumors, our results suggest that this cancer might be the most suitable target for a metformin cancer chemoprevention trial.
